Shenzhen Chipscreen Biosciences Co., Ltd.: history, ownership, mission, how it works & makes money

From a group of returned Ph.D. experts who founded the company in March 2001 to becoming the first biopharma on Shanghai's STAR Market under 688321.SH in 2018, Shenzhen Chipscreen Biosciences has built a data-rich, globally oriented drug developer that blends AI-assisted design and chemical genomics with GMP manufacturing and clinical translation across hubs in Shenzhen, Chengdu, Beijing, Shanghai and the U.S.; today the group - which set up Chipscreen Biosciences (United States) Limited in October 2020 and launched a Phase 1b/2 U.S. trial for chiauranib in August 2022 - reports 1,060 employees as of December 2024 (+0.28% year-on-year), has filed over 700 invention patents (more than 200 granted), and turned to profitability with a net profit attributable to the parent of 29.59 million yuan in August 2025; with 407.81 million shares outstanding (November 2025), a market cap of about 11.17 billion yuan, insider ownership at 5.45% and institutional stakes of 6.76%, Chipscreen monetizes through commercialization and licensing of original drugs-most notably chidamide (Epidaza®)-while advancing a diversified pipeline including chiglitazar, chiauranib and CS12192, navigating market volatility (52-week range: 14.86-44.99 yuan) and shareholder moves such as Boao Bio's announced up-to-3% reduction plan in September 2025.

Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) - Intro

• Founded March 2001 by senior Ph.D. returnee experts from the United States focused on original small-molecule drug R&D.
• October 2020: established Chipscreen Biosciences (United States) Limited in New Jersey to advance global development of drug candidates.
• 2018: became the first biopharmaceutical enterprise listed on the Shanghai Stock Exchange STAR Market (stock code 688321.SH).
• August 2022: initiated a Phase 1b/2 clinical trial in the United States for Chiauranib (CS2164) targeting multiple oncological indications, including Small Cell Lung Cancer (SCLC).
• December 2024: employed 1,060 people, a 0.28% increase versus the prior year.
• August 2025: reported net profit attributable to the parent company of ¥29.59 million, reversing a loss in the same period the prior year.

• Publicly listed on the Shanghai STAR Market (688321.SH); ownership split between institutional investors, retail shareholders and management/investor insiders typical of listed biotech firms.
• International subsidiary in the U.S. (New Jersey) to support global clinical development and licensing partnerships.
• Governance includes a board of directors and scientific leadership drawn from the founding team of Ph.D. returnees and external independent directors.

• Mission: discover, develop and commercialize original small-molecule anti-cancer therapies addressing high unmet medical needs globally.
• Strategic priorities: advance proprietary pipeline (e.g., Chiauranib/CS2164), expand global clinical footprint, pursue strategic collaborations and out-licensing, and develop a commercial pathway in China and abroad.

• Discovery: in-house medicinal chemistry and translational biology to produce novel small molecules.
• Preclinical: GLP toxicology and IND-enabling studies to support regulatory filings.
• Clinical: running Phase 1/2 trials (including U.S. trials for CS2164) to generate safety and efficacy data for later-stage development or partnering.
• Globalization: U.S. subsidiary facilitates U.S./global trials, investigator relationships and potential partnerships/license deals.

• R&D-driven revenue model: milestone and upfront payments from licensing/partnership agreements, and potential future product sales upon commercialization.
• Non-dilutive income sources: government grants and research subsidies common in China for innovative biopharma.
• Capital markets: equity financing via public listing (STAR Market) and follow-on offerings to fund clinical programs.
• Service/technology collaborations: preclinical CRO-style collaborations or co-development agreements with larger pharma/biotech partners.

Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS): History

• Public listing: STAR Market (Shanghai) under ticker 688321.SH.
• Founder & controlling executive: Dr. Xian-Ping Lu - founder, chairman, general manager, CEO, and president.
• Principal business model: discovery, development, and out-licensing/commercialization of small-molecule therapeutics in oncology and related areas.

• Drug discovery & preclinical R&D funded by equity, grants, and partnerships.
• Advancing candidates through clinical trials to create value inflection points that support licensing deals or direct commercialization.
• Out-licensing or co-development agreements with larger pharma provide milestone and royalty streams once compounds progress.
• Occasional strategic disposals or equity financing to fund pipeline milestones and operations.

• Significant public float: with insiders at 5.45% and institutions at 6.76%, a large portion of shares is held by other external investors and retail holders.
• Share price volatility reflected in a wide 52-week range (14.86-44.99 yuan), indicating sensitivity to clinical news, financing events, and broader biotech market sentiment.
• Active shareholder moves (e.g., Boao Bio's announced reduction up to 3% in Sep 2025) can influence liquidity and trading dynamics over defined windows.

Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS): Ownership Structure

• Core mission: provide accessible, clinically needed innovative drugs globally under the philosophy 'Constant Innovation For Life.'
• Therapeutic focus: oncology, metabolic, autoimmune, CNS, antiviral agents.
• Discovery approach: AI-assisted drug design + chemical genomics to enable first-in-class/best-in-class programs.

• Drug discovery & IP: Develop proprietary NME (new molecular entity) candidates using AI/chemical genomics; build value via a robust patent portfolio (700+ filings).
• Clinical development & licensing: Advance clinical-stage assets (internal or in collaboration) and monetize through out-licensing, co-development or milestone royalties.
• Manufacturing & supply: Own GMP production capacity to support clinical and commercial supply, reducing COGS and enabling contract supply opportunities.
• Partnerships & government programs: Leverage participation in national programs (863 and Significant New Drug Development) for funding, grants and validation.

Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS): Mission and Values

• Integrated technology platform: Combines AI-assisted molecular design, high-throughput screening, chemical genomics and translational biology to accelerate hit-to-lead and lead optimization stages.
• Research footprint: R&D centers in Shenzhen and Chengdu concentrate on target discovery, early medicinal chemistry and preclinical validation.
• Translational & manufacturing capabilities: A GMP production base supports production of clinical trial materials and commercial supplies to ensure supply-chain continuity.
• Clinical & commercial organization: A clinical research center in Beijing supports trial execution; a commercial center in Shanghai manages marketing, pricing and sales operations in China.
• Global reach: Chipscreen Biosciences (United States) Limited (est. October 2020) facilitates overseas IND filings, global partnerships and out-licensing/commercialization strategies.

• Drug discovery and development: Value creation through internal discovery programs (small molecules) with the goal of developing proprietary, first-in-class or best-in-class therapeutics.
• Out-licensing and partnerships: Monetization via licensing deals and co-development agreements with domestic and international partners for regional commercialization rights and milestone payments.
• Clinical supply and manufacturing: Revenue and cost control from in-house GMP manufacturing for clinical and commercial batches.
• Service and collaboration income: Research collaboration fees, milestone receipts and royalties on marketed products developed internally or in partnership.

• HUYA Bioscience International: Licensing agreement covering development and commercialization of chidamide (and/or other programs) outside China - providing upfront, milestone and royalty structures to capture international value.
• Domestic and international alliances: Multiple collaboration agreements for preclinical development, IND-enabling studies and regional commercialization support.

• Pipeline scale: Multi-program portfolio spanning oncology, immunology and metabolic diseases with programs at discovery, preclinical and clinical stages (dozens of candidate molecules across stages).
• National science projects: Active participant in national-level initiatives - multiple 863 Program projects and Significant New Drug Development projects - reflecting governmental recognition and funding support.

• Upfront payments and milestones from licensing deals (development, regulatory, sales milestones).
• Royalties on net sales from partnered/commercialized products outside or inside China depending on agreements.
• Direct sales in China via the Shanghai commercial center for marketed products originating from internal programs or in-licensed assets.

• Participation in multiple 863 Program projects, providing technology development funding and strategic alignment with national biotech priorities.
• Involvement in Significant New Drug Development programs, supporting IND-enabling studies and clinical development financing.

Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS): How It Works

• Core commercial product: chidamide (Epidaza®) - an oral, selective HDAC inhibitor approved in China and the major near-term revenue driver.
• Pipeline-driven growth: development-stage assets (chiglitazar, chiauranib, CS12192, others) provide future value creation through internal development, co-development and licensing deals.
• Partnerships and licensing: strategic collaborations (including a licensing arrangement with HUYA Bioscience International for chidamide's development and commercialization outside China) expand addressable markets and share development/commercial risk.
• National science programs: active participation in China's 863 and Significant New Drug Development programs, securing funding, technology validation and regulatory support.

• Revenue model components:
  • Product sales - chiefly chidamide (domestic sales; hospital/oncology channels).
  • Out-licensing / milestone & royalty income - agreements for ex-China territories or co-development partners.
  • Service / collaboration income - sponsored R&D, joint projects with academic or industry partners.
  • Grants & program funding - government-sponsored national science & technology programs (863, Significant New Drug Development).

• Recent financial & market context:
  • Revenue growth to date has been driven primarily by chidamide sales in China; the company has reported year-on-year increases in product revenues in periods following commercial launch.
  • Reported financial disclosures in English are limited; detailed margin and cash flow line-item comparatives are more readily available in Chinese filings and periodic reports.
  • Market capitalization and share price have shown meaningful fluctuations, reflecting pipeline news, clinical readouts, regulatory progress and broader biotech sentiment (52-week range shown above).

• Key operational levers that convert R&D into revenue:
  • Efficient clinical development execution and favorable regulatory decisions (accelerated approvals or breakthrough designations where applicable).
  • Commercial execution for chidamide in hospital oncology channels and expanding formulary access.
  • Out-licensing and international partnerships to monetize ex-China rights or co-develop pipeline assets.
  • Continued participation in government R&D programs to secure non-dilutive funding and national-level validation.

Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS): How It Makes Money

• Flagship product revenue: chidamide (Epidaza®) - an HDAC inhibitor first approved in China in 2014 for relapsed/refractory peripheral T‑cell lymphoma (PTCL) and later explored in breast cancer indications - generates recurring sales from hospital procurement and oncology prescriptions.
• Partnering and licensing: out‑licensing agreements (notably with HUYA Bioscience International for ex‑China development/commercialization) generate milestone payments, royalties and co‑development income streams.
• Pipeline value capture: clinical progression and eventual approvals for assets such as chiglitazar, chiauranib and CS12192 create future sales and additional licensing income.
• Government contracts and grants: participation in national programs (863 Program and Significant New Drug Development projects) supplies non-dilutive funding and subsidized development support.

• Leadership in epigenetic therapeutics in China via chidamide establishes strong brand and clinician adoption in T‑cell lymphoma and exploratory oncology combinations.
• Diversified clinical portfolio (chiglitazar - PPAR agonist for metabolic/oncology indications; chiauranib - multi‑kinase inhibitor; CS12192 - immuno‑inflammatory target) reduces single‑asset risk and positions multiple potential revenue pillars over the next 3-7 years.
• Strategic partnerships (including HUYA for ex‑China chidamide) de‑risk international commercialization and create milestone/royalty upside.
• Active participation in major national R&D programs (863, Significant New Drug Development) demonstrates alignment with state priorities and access to public funding/support.
• Market valuation has been volatile - 52‑week share price range: 14.86-44.99 yuan - reflecting investor sentiment tied to clinical readouts, regulatory news, and broader biotech market dynamics.

• Direct product sales: hospital tenders, oncology prescriptions and supply agreements for Epidaza® (chidamide).
• Out‑licensing & collaboration: up‑fronts, development milestones, regulatory milestones, and tiered royalties on ex‑China sales.
• R&D funding: grants and awards from national programs reduce cash burn and enable capital reallocation to prioritized programs.
• Potential future streams: new drug approvals from internal pipeline and possible M&A or asset sales.